Neuromod’s Tinnitus Treatment Device Validated by Clinical Trial Results
Nature Communications published peer-reviewed results of Neuromod's TENT-A3 clinical trial, validating its tinnitus treatment device, Lenire.
Tag: clinical trials
All
Latest
All
Latest
Clinical Trial of Gene Therapy for Genetic Hearing Loss Gets Positive Results
The trial demonstrated pharmacologic hearing restoration within 30 days of AK-OTOF gene therapy administration in the first participant.
All
Latest
Auris Medical Completes Enrollment in Phase 2 Study for Vertigo Drug
The Company expects to release interim results from TRAVERS and commence Part B of the trial in the coming weeks.
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Read More
Otonomy Initiates Clinical Trial for Tinnitus Drug
The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus.
Read More
Audion Therapeutics and Regain Consortium Report Positive Phase I Results from Drug to Treat SNHL
LY3056480 mediated Notch inhibition is aimed at regeneration of inner ear sensory hair cells that are lost with advancing age.
Read More
Otonomy Presents Data on OTO-413 Therapy for Hearing Loss
These preclinical data, demonstrating the potential of intratympanic BDNF to repair cochlear synaptopathy—an underlying cause of hearing loss including speech-in-noise hearing difficulty—are being presented as part of the Society for Neuroscience (SfN) Annual Meeting in San Diego, November 3-7, 2018.
Read More
NF2 Trial: An Interview with Rick Friedman, MD, PhD
Hearing Review interviewed Rick Friedman, MD, PhD, about NF2 and an NF2 clinical that is underway in Los Angeles and at 12 other sites in the US. The trial uses the chemotherapy drug Avastin (bevacizumab) as a potential therapy for shrinking NF2 tumors, or stemming their growth.
Read More
Drug Trial Results Offer Hope for Ménière’s, Tinnitus Patients
Otonomy, which develops and commercializes therapeutics for ear diseases and disorders, reported that its development of investigational drugs to help patients with Ménière’s disease and tinnitus, have had positive results in clinical trials.
Read More
Auris Medical Begins Phase 3 Trial for Sudden Deafness Drug
Auris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Read More
Clinical Trial Tests Remote Care for Cochlear Implant Users
The University of Southampton Auditory Implant Service has launched a new clinical trial involving 60 patients, half of whom will use an online care package to determine whether the routine annual clinic check-up of hearing and device status can be replaced with a personalized online version.
Read More
Auris Medical Enrolls First Patient in HEALOS Trial of Hearing Loss Drug
Auris Medical Holding AG, a Swiss biopharmaceutical company, announced enrollment of the first patient into the HEALOS clinical trial to test the drug, AM-111, as a therapy for sudden hearing loss. The trial involves 255 patients suffering from acute severe to profound hearing loss within 72 hours from onset.
Read More
Magnetic Pulses to Brain Bring Relief for Tinnitus Patients
More than half the participants who completed TMS sessions on 10 consecutive workdays found their tinnitus symptoms were alleviated for at least six months.
Read More
Auris Medical Collaborates with Cochlear on Clinical Trial
Auris Medical Holding and Cochlear Limited announced they will collaborate on a planned randomized placebo-controlled clinical trial in the US (the REACH trial) to investigate otoprotection during cochlear implant (CI) surgery.
Read More
Auris Medical Publishes on New Tinnitus Drug
Auris Medical, a Switzerland-based clinical-stage company developing therapeutics for hearing conditions, announced publications in two peer-reviewed journals related to AM-101, the company’s drug developed for treating acute inner ear tinnitus.
Read More
New Drugs for Hearing Loss Expected in 5 Years
According to the 2015 Hearing Progress Report from Action on Hearing Loss (formerly RNID), the first drugs to treat or prevent hearing conditions could be available in 5 years.
Read More
ABI Trial Helps Children Born without Hearing Nerve
Hearing experts at the University of Southern California’s Keck School of Medicine and other institutions are conducting an ABI trial aimed at helping children born without a hearing nerve.
Read More
New York Times: New Drug Studies Target Ear and Balance Ailments
A January 9, 2015 New York Times article reviews pharmaceutical companies’ pursuit of drug therapies for ear and balance ailments, including hearing loss, tinnitus, vertigo.
Read More